Table 5.

Percentage of reduction from the initial PANSS_0–6 total and subscale scores after 8 weeks of treatment with olanzapine, risperidone, clozapine or other antipsychotics in schizophrenia patients subdivided according to the COMT rs4680 genotypes.

	Olanzapine n = 190			Risperidone n = 99			Clozapine n = 102			Other antipsychotics n = 130
	Median	Range	IR	Median	Range	IR	Median	Range	IR	Median	Range	IR
Total PANSS0–6 scores reduction after 8 weeks of treatment
COMT rs4680
AA	56.0	83	33	52.4	83	32	50.1	55	23	54.3	83	40
AG	58.2	81	24	58.0	70	28	49.2	66	22	60.0	84	28
GG	49.5	71	23	63.2	76	37	45.5	53	27	54.2	79	33
Kruskal–Wallis ANOVA	H = 7.93; p = 0.019			H = 0.37; p = 0.832			H = 0.04; p = 0.981			H = 1.37; p = 0.505
PANSS0–6 positive symptom scores reduction after 8 weeks of treatment
COMT rs4680
AA	64.5	81	34	62.2	82	30	52.9	75	21	67.6	88	47
AG	63.6	79	31	61.4	86	31	57.7	89	27	64.3	83	30
GG	52.9	84	26	68.8	84	27	53.3	74	28	60.9	90	40
Kruskal–Wallis ANOVA	H = 7.26; p = 0.027			H = 0.18; p = 0.912			H = 0.33; p = 0.850			H = 0.54; p = 0.763
PANSS0–6 negative symptom scores reduction after 8 weeks of treatment
COMT rs4680
AA	37.7	80	33	37.2	89	47	28.9	73	13	37.9	88	55
AG	43.5	86	37	48.1	189	41	28.9	67	23	47.6	86	55
GG	36.4	96	29	44.0	92	42	28.2	72	22	44.4	80	47
Kruskal–Wallis ANOVA	H = 3.88; p = 0.144			H = 1.85; p = 0.398			H = 0.15; p = 0.930			H = 0.12; p = 0.944
PANSS0–6 general psychopathology scores reduction after 8 weeks of treatment
COMT rs4680
AA	51.2	95	34	48.4	86	26	51.9	58	24	44.4	83	30
AG	55.9	93	25	56.8	86	30	45.4	74	23	56.3	87	28
GG	48.3	75	17	53.6	78	39	43.9	46	25	50.0	106	34
Kruskal–Wallis ANOVA	H = 5.218; p = 0.074			H = 0.22; p = 0.897			H = 1.60; p = 0.449			H = 3.61; p = 0.164

Values are given as median, range and interquartile range (IR).

n number of subjects, PANSS positive and negative syndrome scale.